Biospring Partners

Labviva, Inc. is a digital marketplace based in Somerville, Massachusetts, that connects researchers with suppliers of life science products, including reagents, chemicals, and instrumentation. Founded in 2015, the company offers a wide range of laboratory supplies such as antibodies, biological kits, buffers, chromatography materials, and laboratory equipment. Labviva's platform is designed to enhance procurement efficiency by providing real-time inventory tracking, AI-driven purchase automation, and insights into lab purchasing trends. This enables clients to manage their supply chains more effectively, preserve contract pricing with preferred vendors, and establish direct partnerships, all while simplifying content management for suppliers.

Labviva, Inc. is a digital marketplace based in Somerville, Massachusetts, that connects researchers with suppliers of life science products, including reagents, chemicals, and instrumentation. Founded in 2015, the company offers a wide range of laboratory supplies such as antibodies, biological kits, buffers, chromatography materials, and laboratory equipment. Labviva's platform is designed to enhance procurement efficiency by providing real-time inventory tracking, AI-driven purchase automation, and insights into lab purchasing trends. This enables clients to manage their supply chains more effectively, preserve contract pricing with preferred vendors, and establish direct partnerships, all while simplifying content management for suppliers.

Abzena plc is a biopharmaceutical services company that specializes in the development and manufacturing of biologics and antibody-drug conjugates (ADCs). Operating internationally, it provides a comprehensive range of technologies and solutions that support the discovery, development, and production of biopharmaceutical products. Abzena's offerings include advanced antibody engineering, immunogenicity assessment, and various bioassay and bioanalytic services. The company assists clients from initial concept through to clinical development, focusing on enhancing the efficacy and safety of biotherapeutics. Its services also encompass peptide synthesis, process development, and the characterization of drug conjugates. By partnering with biopharmaceutical companies and academic institutions, Abzena aims to drive innovation and improve therapeutic outcomes for patients. Founded in 2014 and headquartered in Cambridge, United Kingdom, Abzena has positioned itself as a key player in the biologics research sector.

Kiniciti is a platform created by Welsh, Carson, Anderson & Stowe to partner with life science companies developing cell and gene therapies. It offers resources, expertise, and capital to help these companies scale and deliver patient value, focusing on opportunities that leverage technology and capabilities to drive transformational change. The aim is to accelerate the advancement and adoption of cell and gene therapies and to ensure therapies reach patients in need by addressing development, manufacturing, and delivery bottlenecks.

ixLayer is a leader in the health-tech sector, specializing in precision health testing solutions that facilitate virtual health testing for various stakeholders, including health systems, payors, biopharma, and health-focused organizations. Established in 2018, ixLayer's platform offers comprehensive solutions encompassing technical, security, regulatory, and user experience aspects of complex health testing. As the demand for remote and virtual care continues to grow, ixLayer enhances patient engagement and preventative health strategies by enabling real-time health and wellness lab testing. The platform can be seamlessly integrated with existing patient engagement systems and portals, allowing organizations to efficiently launch and manage testing programs. Serving millions of patients, ixLayer has developed and implemented numerous testing initiatives for large organizations, healthcare systems, and government agencies, contributing to a progressive shift towards telehealth.

Abzena plc is a biopharmaceutical services company that specializes in the development and manufacturing of biologics and antibody-drug conjugates (ADCs). Operating internationally, it provides a comprehensive range of technologies and solutions that support the discovery, development, and production of biopharmaceutical products. Abzena's offerings include advanced antibody engineering, immunogenicity assessment, and various bioassay and bioanalytic services. The company assists clients from initial concept through to clinical development, focusing on enhancing the efficacy and safety of biotherapeutics. Its services also encompass peptide synthesis, process development, and the characterization of drug conjugates. By partnering with biopharmaceutical companies and academic institutions, Abzena aims to drive innovation and improve therapeutic outcomes for patients. Founded in 2014 and headquartered in Cambridge, United Kingdom, Abzena has positioned itself as a key player in the biologics research sector.